Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma

Metastatic Chondrosarcoma Clinical Trial

Official title:
A Phase I Trial of Lattice Stereotactic Body Radiation Therapy (Lattice SBRT) for Localized Unresectable or Metastatic Conventional Type Chondrosarcoma

Status Withdrawn

Clinical Trial Summary

Unresectable (including metastatic) conventional chondrosarcoma requires high dose radiation for local control. Radiation Oncologists have traditionally used long radiation courses and concern for toxicity to surrounding organs at risk. Stereotactic body radiation therapy (SBRT) has the ability to deliver high doses of radiation in a manner that may improve clinical response but has size limitations. SBRT delivered with lattice radiotherapy (LRT) may safely dose escalate smaller portions of the tumor and also provide improved cancer control. This study is to evaluate the safety and initial efficacy of this treatment approach.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04098887
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Withdrawn
Phase	N/A
Start date	October 31, 2020
Completion date	November 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03670069` - Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas	Phase 1
Recruiting	`NCT06176989` - Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors	Phase 2
Active, not recruiting	`NCT01267955` - Vismodegib in Treating Patients With Advanced Chondrosarcomas	Phase 2
Completed	`NCT01330966` - Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma	Phase 2